For the twelve-month period ended December 31, as compared to the same period of 2021: Revenue of between $447M and $450M, an increase of 20%: Reported 124,800 tests to clinical customers and 26,000 tests to biopharma customers, an increase of 42% and 40%, respectively
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Gordon Haskett wonders if Guardant could be ‘shoehorned’ into Agilent search
- Guardant Health initiated with an Outperform at Scotiabank
- Sell these stocks now, proven algorithm says
- Goldman says Guardant selloff, Exact Science rally an overreaction
- Guardant Health price target raised to $70 from $65 at BofA